Recurrent Status Epilepticus and SARS-CoV-2 infection: the “perfect storm”.

Main Article Content

CRISTIAN DEANA
GIADA PAULETTO
LORENZO VERRIELLO
CHRISTIAN LETTIERI
ILARIA DEL NEGRO
ANNACARMEN NILO
MARIAROSARIA VALENTE
GIAN LUIGI GIGLI
LUIGI VETRUGNO

Keywords

status epilepticus, delirium, anti-seizure medications, EEG monitoring, SARS-CoV-2

Abstract

Respiratory involvement is the most common clinical manifestation of COVID-19, but neurological symptoms and complications are increasingly being recognized. Seizures and status epilepticus (SE) have been described as possible consequences of hypoxia and metabolic derangements during SARS-CoV-2 infection, direct viral invasion of the central nervous system, or as para or post-infectious complications. Single episodes of SE have been described, occurring during the acute phase of COVID-19 or once the patients have been recovered.


Herein, we present the case of a patient with a positive serology test for SARS-CoV-2 (IgG+, IgM-) and recurrent SE occurring within 36 days. Diagnostic work-up ruled out other known causes of SE. A post-COVID-19 infectious inflammatory/immune response is hypothesized as the possible trigger of SE.

Downloads

Download data is not yet available.
Abstract 13 |

References

1. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet 2020; 19(9): 767-83. Doi: 10.1016/S1474-4422(20)30221-0.
2. Deana C, Verriello L, Pauletto G, Corradi F, Forfori F, Cammarota G, et al. Insights into neurological dysfunction of critically ill COVID-19 patients. Trends Anaesthesia Critic Care 2020; In press. Doi: 10.1016/j.tacc.2020.09.005.
3. Gigli GL, Vogrig A, Nilo A, Fabris M, Biasotto A, Curcio F, et al. HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome. Neurol Sci 2020; 41(12): 3391-4. Doi: 10.1007/s10072-020-04787-7.
4. Carroll E, Neumann H, Aguero-Rosenfeld ME, Lighter J, Czeisler BM, Melmed K, Lewis A. Post-COVID-19 inflammatory syndrome manifesting as refractory status epilepticus. Epilepsia 2020; 61(10): e135-e139. Doi: 10.1111/epi.16683.
5. Vollono C, Rollo E, Romozzi M, Frisullo G, Servidei S, Borghetti A, Calabresi P. Focal status epilepticus as unique clinical feature of COVID-19: a case report. Seizure 2020; 78: 109-112. Doi: 10.1016/j.seizure.2020.04.009.
6. Dono F, Carrarini C, Russo M, De Angelis MV, Anzellotti F, Onofrj M, Bonanni L. New-onset refractory status epilepticus (NORSE) in post SARS-CoV-2 autoimmune encephalitis: a case report. Neurol Sci 2021; 42(1): 35-38. Doi: 10.1007/s10072-020-04846-z.
7. Chen W, Toprani S, Werbaneth K, Falco-Walter J. Status epilepticus and other EEG findings in patients with COVID-19: a case series. Seizure 2020; 81: 198-200. Doi: 10.1016/j.seizure.2020.08.022.
8. Somani S, Pati S, Gaston T, Chitlangia A, Agnihotri S. De novo status epilepticus in patients with COVID-19. Ann Clin Transl Neurol 2020; 7(7): 1240-4. Doi: 10.1002/can.3.51071.
9. Balloy G, Leclair-Visonneau L, Péréon Y, Magot A, Peyre A, Mahé PJ, Derkinderen P. Non-lesional status epilepticus in a patient with coronavirus disease 2019. Clin Neurophysiol 2020; 131(8): 2059-61. Doi: 10.1016/j.clinph.2020.05.005.
10. Pilotto A, Odolini S, Masciocchi S, Comelli A, Volonghi I, Gazzina S, et al. Steroid-responsive encephalitis in coronavirus disease 2019. Ann Neurol 2020; 88(2): 423-7. Doi: 10.1002/ana.25783.
11. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P, Del Campo R, Ciapponi A, et al. False-negative results of initial RT-PCR assays for COVID-19: a systematic review. PLos One 2020; 15(12): e0242958. Doi: 10.1371/journal.pone.0242958.
12. Hosseini AA, Shetty AK, Sprigg N, Auer DP, Constantinescu CS. Delirium as a presenting feature in COVID-19: neuroinvasive infection or autoimmune encephalopathy? Brain Behav Immun 2020; 88: 68-70. Doi: 10.1016/j.bbi.2020.06.012.

Most read articles by the same author(s)